#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Clinical Osteology / 2019 - 2

Current opinion on premenopausal osteoporosis

Czech version

Authors: Payer Juraj;  Smaha Juraj;  Kužma Martin;  Jackuliak Peter;  Killinger Zdenko
Authors‘ workplace: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava
Published in: Clinical Osteology 2019; 24(2): 75-81
Category:

Overview

In contrast to postmenopausal subjects, diagnosis and treatment of osteoporosis in young women remain poorly defined. A low bone mineral density in premenopausal women is not associated with the same risk of fractures as in postmenopausal women, therefore diagnosis requires not only densitometry but depends on the consideration of other risk factors. Most cases of premenopausal osteoporosis are associated with chronic diseases known to affect bone metabolism. Treatment of the underlying disease may improve bone density as well as bone quality. Rarely, a bone-specific therapy may be used, although quality evidence is scarce. This article will review current opinion on definition, diagnosis and treatment of premenopausal osteoporosis.

Keywords:

DXA – prevention of osteoporosis – premenopausal osteoporosis – risk of fracture

Sources
  1. Martinez-Morillo M, Grados D, Holgado S. Premenopausal osteoporosis: how to treat? Reumatol Clin 2012; 8(2): 93–97. Dostupné z DOI: <http://dx.doi.org/10.1016/j.reuma.2011.05.011>
  2. Weaver CM, Gordon CM, Janz KF et al. The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: a systemic review and implementation recommendations. Osteoporos Int 2016; 27(4): 1281–1386. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–015–3440–3>.
  3. Schousboe JT, Shepherd JA, Bilezikian JP et al. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom 2013; 16(4): 455–466. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jocd.2013.08.004>.
  4. Ferrari SL, Bianchi ML, Eisman JA et al. IOF Committee of scientific Advisors Working Group on Osteoporosis Pathophysiology. Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 2012; 23(12): 2735–2748. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–012–2030-x>.
  5. Cohen A, Recker RR, Lappe J et al. Premenopausal women with idiopathic low-trauma fractures and/or low bone mineral density. Osteoporos Int 2012; 23(1): 171–182. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–011–1560-y>.
  6. ISCD Official Positions – Adult. Indications for Bone Mineral Density (BMD) Testing 2019. Dostupné z WWW: <https://www.iscd.org/official-positions/2019-iscd-official-positions-adult/>.
  7. Buckley LG, Fink HA, Cannon M et al. 2017 American College of Rheumatology guideline for the intervention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 2017; 69(8): 1521–1537. Dostupné z DOI: <http://dx.doi.org/10.1002/art.40137>.
  8. Ferrari SL, Chevalley T, Bonjour JP et al. Childhood fractures are associated with decreased bone mass gain during puberty: an early marker of persistent bone fragility? J Bone Miner Res 2006; 21(4): 501–507. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.051215>.
  9. Kužma M, Vaňuga P, Binkley N et al. High Serum Fractalkine is associated with Lower Trabecular Bone Score in Premenopausal Women with Graves' Disease. Horm Metab Res 2018; 50(8): 609–614. Dostupné z DOI: <http://dx.doi.org/10.1055/a-0633–2814>.
  10. Ross AC, Manson JE, Abrams SA et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96(1): 53–58. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2010–2704>.
  11. Špániková B. Sekundárna osteoporóza pri nádorových ochoreniach. Clin Osteol 2018; 23(1): 9–17.
  12. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early stage breast cancer: 5-year follow-up of the ABCSG-12 bone mineral density substudy. Lancet Oncol 2008; 9(9): 840–849. Dostupné z DOI: <http://dx.doi.org/10.1016/S1470–2045(08)70204–3>.
  13. Hershman DL, McMahon DJ, Crew KD et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab 2010; 95(2): 559–566. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2009–1366>.
  14. Delmas PD, Balena R, Confravreux E et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15(3): 955–962. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.1997.15.3.955>.
  15. Hines SL, Mincey BA, Sloan JA et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2009; 27(7): 1047–1053. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2008.19.1783>.
  16. Haderslev KV, Tjellesen L, Sorensen HA, Straun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease. Gastroenterology 2000; 119(3): 639–646. Dostupné z DOI: <http://dx.doi.org/10.1053/gast.2000.16518>.
  17. Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev 2014; (3):CD002010. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD002010.pub4>.
  18. Misra M, Golden NH, Katzman DK. State of the art systematic review of bone disease in anorexia nervosa. Int J Eat Dis 2016; 49(3): 276–292. Dostupné z DOI: <http://dx.doi.org/10.1002/eat.22451>.
  19. Misra M, Klibanski A. Anorexia nervosa and bone. J Endcrinol 2014; 221(3): R163-R176. Dostupné z DOI: <http://dx.doi.org/10.1530/JOE-14–0039>.
  20. Curtis J, Westfall AO, Allison J et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006; 55(3): 420–426. Dostupné z DOI: <http://dx.doi.org/10.1002/art.21984>.
  21. Van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2005; 20(8): 1487–1494. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.2005.20.8.1486>.
  22. Payer J, Killinger Z. Osteoporóza. Herba: Bratislava 2012. ISBN 9788089171941.
  23. Peris P, Monega A, Martinez MA et al. Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis. Clin Rheumatol 2007; 26(6): 958–961. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067–006–0405–0>.
  24. [World health organization]. Guideline: calcium supplementation in pregnant women. World Health Organization 2013. ISBN 978–92–4-150537–6. Dostupné z WWW: <https://apps.who.int/iris/bitstream/handle/10665/85120/9789241505376_eng.pdf>.
  25. Holick, MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96(7): 1911–1930. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011–0385>. Erratum in J Clin Endocrinol Metab 2011; 96(12): 3908.
  26. Kalkwarf HJ, Specker BL, Bianchi DC et al. The effet of calcium supplementation on bone density during lactation and after weaning. N Engl J Med 1997; 337(8): 523–528. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199708213370803>.
  27. O’Sullivan SM, Grey AB, Singh R. et al. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporosis Int 2006; 17(7): 1008–1012. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–006–0112–3>.
  28. Choe EY, Song JE, Park KH et al. Effect of teriparatid on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures. J Bone Miner Metab 2012; 30(5): 596–601. Dostupné z DOI: <http://dx.doi.org/10.1007/s00774–011–0334–0>.
  29. Fink HA, MacDonald R, Forte ML et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Int Med 2019; 171(1): 37–50. Dostupné z DOI: <http://dx.doi.org/10.7326/M19–0533>.
  30. Wotton CJ, Green J, Brown A et al. Use of oral bisphosphonates and risk of hospital admission with osteonecrosis of the jaw: Large prospective cohort study in UK women. Bone 2019; 124: 69–74. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2019.04.003>.
  31. Wood J, Bonjean K, Ruetz S et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharm Exp Ther 2002; 302(3): 1055–1061. Dostupné z DOI: <http://dx.doi.org/10.1124/jpet.102.035295>.
  32. Sokal A, Elefant E, Leturcq T et al. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. Osteoporos Int 2019; 30(1): 221–229. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–018–4672–9>.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology
Profesor Jaroslav Blahoš a slovenská osteológia
Profesor Jaroslav Blahoš, jak jsem ho znal
Calcitonin: hormone into oblivion
Cushing’s syndrome, glucocorticoids and bone
Can affecting of subchondral bone slow the progression of osteoarthritis?
Prevention and treatment of osteoporosis: causal or symptomatic?
Extraskeletal risk factors for fractures in older age
Article was published in

Clinical Osteology

Issue 2
2019 Issue 2
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#